In a patient with markedly elevated transaminases (AST 1700 U/L, ALT 970 U/L) who is taking methenamine, divalproex (valproic acid), ivabradine, leflunomide, and nitrofurantoin, can these medications cause liver injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Multiple Medications in This Regimen Can Cause Severe Liver Injury

With transaminases this markedly elevated (AST 1700, ALT 970), divalproex and leflunomide are the most likely culprits and should be immediately discontinued. Both carry FDA black box warnings for potentially fatal hepatotoxicity.

High-Risk Hepatotoxic Agents

Divalproex (Valproic Acid) - HIGHEST CONCERN

  • FDA Black Box Warning: Hepatic failure resulting in fatalities has occurred, usually within the first 6 months of treatment 1
  • Fatal hepatotoxicity may be preceded by non-specific symptoms including malaise, weakness, lethargy, anorexia, and vomiting 1
  • Causes hepatocellular injury through multiple mechanisms: oxidative stress, reactive metabolite formation (Δ4VPA), mitochondrial dysfunction, carnitine depletion, and impaired fatty acid β-oxidation 2, 3
  • Can cause acute liver failure with hepatic encephalopathy even with normal baseline liver function 4
  • Action required: Immediate discontinuation with these transaminase levels

Leflunomide - SECOND HIGHEST CONCERN

  • FDA Warning: Rare cases of severe liver injury with fatal outcomes, most occurring within 6 months 5
  • Requires baseline and monthly ALT monitoring for first 6 months, then every 6-8 weeks 5
  • FDA guidance for these levels: ALT >3× ULN requires immediate discontinuation AND cholestyramine washout procedure 5
  • The active metabolite (M1) has a half-life >1 week, requiring active drug elimination with cholestyramine or activated charcoal to reduce plasma levels from weeks to approximately 1 day 5

Nitrofurantoin - MODERATE CONCERN

  • Well-documented cause of drug-induced liver injury, can occur after prolonged use (even years) 6
  • Can lead to acute liver failure or autoimmune-like hepatitis 6
  • Approximately 10% risk of death or need for transplantation when jaundice develops 6

Lower-Risk Agents

Methenamine

  • Minimal hepatotoxicity reported in literature
  • Not a primary concern with these transaminase levels

Ivabradine

  • Not recognized as a significant hepatotoxin
  • Unlikely contributor to this degree of liver injury

Immediate Management Algorithm

Step 1: Discontinue hepatotoxic drugs immediately

  • Stop divalproex NOW
  • Stop leflunomide NOW and initiate cholestyramine washout (8g three times daily for 11 days) 5
  • Consider stopping nitrofurantoin

Step 2: Assess severity and need for hospitalization

  • Check INR/PT, albumin, total and direct bilirubin immediately
  • Assess for hepatic encephalopathy (mental status changes, asterixis)
  • These transaminase levels (AST 1700, ALT 970) represent severe hepatocellular injury (R-value calculation would show hepatocellular pattern)

Step 3: Exclude other causes

  • Viral hepatitis panel (HBsAg, anti-HCV, HBV DNA if positive)
  • Autoimmune markers (ANA, anti-smooth muscle antibody)
  • Acetaminophen level
  • Abdominal imaging to exclude biliary obstruction or infiltrative disease 7

Step 4: Monitor for progression

  • Daily liver biochemistries until downtrending
  • For hepatocellular injury, expect ≥50% decrease in ALT within 8 days if drug-induced (highly suggestive); within 30 days is important for diagnosis 8

Critical Pitfalls to Avoid

  1. Do not rechallenge with divalproex or leflunomide - especially given this severity of injury 5
  2. Do not delay leflunomide washout - the long half-life of the active metabolite means continued hepatotoxicity without active elimination 5
  3. Do not assume single drug causality - polypharmacy increases DILI risk, particularly with multiple hepatotoxins 6
  4. Do not miss acute liver failure criteria - INR ≥1.5 with any mental status changes requires immediate transplant center evaluation 9

Causality Assessment

Use RUCAM (Roussel-Uclaf Causality Assessment Method) scale for formal causality determination, particularly important with multiple potential hepatotoxins 8. The temporal relationship, degree of elevation, and response to drug withdrawal will help establish which agent(s) are responsible.

Given the severity (transaminases >10× ULN), this represents a signal requiring urgent action regardless of which specific drug is causative 9.

References

Research

Drug-induced liver injury due to antibiotics.

Scandinavian journal of gastroenterology, 2017

Research

[Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2024

Research

Drug-induced liver injury.

Drug safety, 2007

Related Questions

What are the chances of drug-induced liver injury in a patient with worsening liver function tests on Zavicefta (Ceftazidime-Avibactam), Aztreonam, Teicoplanin, Anidulafungin, and Colistin?
What is the appropriate dosing regimen for valproic acid (VPA) in adults and children, including starting dose, titration schedule, maximum dose, and special considerations such as hepatic impairment and enzyme‑inducing drug interactions?
How should bilirubin levels be interpreted in a patient with suspected drug‑induced liver injury?
What is the purpose of ordering a Thiopurine Methyltransferase (TPMT) test in a patient with acute drug-induced liver failure?
What is the likely etiology of the mildly elevated total bilirubin and transaminases in a 53‑year‑old woman with borderline hemoglobin A1c and modest dyslipidemia, and how should these liver function abnormalities be evaluated and managed?
What is the appropriate diagnosis and management for thimble bladder (severely contracted bladder with very low functional capacity)?
Is lactulose safe and appropriate for use in prediabetic adults with constipation or mild hepatic encephalopathy, and what dosing and monitoring are recommended?
Are Metamucil (psyllium husk) and polyethylene glycol (PEG 3350) both bulk‑forming laxatives?
In a 63-year-old man with a prostate enlarged to larger than a softball, should a serum prostate-specific antigen (PSA) test be obtained?
In a 63-year-old man with a previously normal prostate-specific antigen (PSA) level who now has a rapidly enlarged prostate the size of a softball and a post‑void residual volume of 500 mL, should a PSA be obtained?
In a 25-year-old woman with rectal bleeding, should an abdominal-pelvic CT scan be ordered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.